|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SMAD4 is frequently inactivated and associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC).
|
31684910 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
|
31569425 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, in pancreatic ductal adenocarcinoma (PDAC) there are only four abundantly common driver mutations (KRAS, CDKN2A, TP53, and SMAD4), which are not currently actionable.
|
31639254 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A prominent function of TGIF1 is suppression of transforming growth factor beta (TGF-β) signaling, whose inactivation is deemed instrumental to the progression of pancreatic ductal adenocarcinoma (PDAC), as exemplified by the frequent loss of the tumor suppressor gene SMAD4 in this malignancy.
|
31268604 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed mutational and immunohistochemical analyses of 4 major genes-KRAS, TP53, CDKN2A, and SMAD4-associated with pancreatic ductal adenocarcinoma progression, as well as targeted next-generation sequencing.
|
30497813 |
2019 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression.
|
30212393 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SMAD4 mutational status correlates with pancreatic ductal adenocarcinoma (PDAC) failure pattern.
|
28983662 |
2018 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genome of pancreatic ductal adenocarcinoma (PDAC) frequently contains deletions of tumour suppressor gene loci, most notably SMAD4, which is homozygously deleted in nearly one-third of cases.
|
28099419 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
|
28160547 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Advances in knowledge: A well-defined tumour margin is an independent CT finding associated with DPC4-expression pancreatic ductal adenocarcinoma.
|
28339284 |
2017 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SMAD4 inactivation by allelic deletion or intragenic mutation mainly occurs in the late stage of human pancreatic ductal adenocarcinoma (PDAC).
|
24625091 |
2014 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
|
24859161 |
2014 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
|
23344532 |
2013 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent whole-exome sequencing had shown that the landscape of the pancreatic ductal adenocarcinoma (PDAC) genome is notable for 4 frequently mutated genes (KRAS, TP53, CDKN2A/p16, and SMAD4/DPC4).
|
23470568 |
2013 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SMAD4 genetic alterations predict a worse prognosis in patients with pancreatic ductal adenocarcinoma.
|
22504380 |
2012 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synergistic action of Smad4 and Pten in suppressing pancreatic ductal adenocarcinoma formation in mice.
|
19901970 |
2010 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of the cases had loss of Dpc4 protein and strong nuclear p53 positivity, similar to the molecular signature found in pancreatic ductal adenocarcinoma.
|
19270646 |
2009 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive human malignancy in which the transforming growth factor beta (TGF-beta) signal transducer, Smad4, is commonly mutated or deleted.
|
16320109 |
2005 |
|
Pancreatic Ductal Adenocarcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma.
|
11751510 |
2001 |